F-1/A: Park Ha Biological Technology Eyes Nasdaq Listing with $6 Million IPO

Park Ha Biological Technology Co., Ltd. plans to raise $6 million through an initial public offering of 1,200,000 ordinary shares, aiming for a Nasdaq listing.

Summary

• Park Ha Biological Technology Co., Ltd., a Cayman Islands holding company, is planning an initial public offering (IPO) to list its ordinary shares on the Nasdaq Capital Market.
• The company intends to offer 1,200,000 ordinary shares at an expected price between $4.00 and $6.00 per share, potentially raising $6 million at the midpoint.
• Park Ha Cayman operates through its subsidiaries in China, specializing in skincare and cosmetic products under the Park Ha brand.
• The company's revenue streams include product sales and franchise fees, with a recent shift towards a higher proportion of revenue from franchise fees.
• For the six months ended April 30, 2024, total revenue was $852,928, a decrease from $1,371,587 in the same period of 2023, primarily due to a decrease in franchise fees.
• Net income for the six months ended April 30, 2024, was $48,900, a significant decrease from $499,796 in the corresponding period of 2023.
• The company faces risks associated with operating in China, including regulatory uncertainties and potential government intervention.
• Investors are cautioned that they are purchasing shares of a Cayman Islands holding company, not a China-based operating company.
• The company's CEO will retain significant voting power post-IPO, potentially leading to conflicts of interest.
• The offering is contingent upon Nasdaq approval, and there is no guarantee of listing approval.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is pursuing growth through an IPO, it also faces challenges such as declining revenue and net income, intense competition, and regulatory risks in China. The high ownership concentration and reliance on third parties add to the uncertainty.

Positives

• The company's revenue increased by 28.12% from $1,919,389 for the year ended October 31, 2022 to $2,459,102 for the year ended October 31, 2023.
• The company plans to use the proceeds from this offering for expanding the scale of its directly-owned stores, purchasing existing product patents, and acquiring our ingredients suppliers.
• The company has a strong and diversified management team with extensive experience in various industries.
• The company has a stable supply chain system with suppliers located in Guangzhou, Shanghai, Zhejiang Province, and Jiangsu Province in China.

Negatives

• The company's revenue decreased to $852,928 for the six months ended April 30, 2024, compared to $1,371,587 for the six months ended April 30, 2023.
• Net income decreased significantly to $48,900 for the six months ended April 30, 2024, from $499,796 for the same period in 2023.
• The company relies on third-party manufacturers and suppliers, posing potential supply chain risks.
• The company is subject to legal and operational risks associated with having all business operations in China.

Risks

• The company faces intense competition in the skincare industry.
• There are limited resources and great challenges in building and maintaining a robust supply chain infrastructure.
• There are challenges in maintaining product consistency and quality.
• The PRC government may intervene or influence the company's operations at any time.
• The company's Ordinary Shares may be prohibited from trading on a national exchange under the Holding Foreign Companies Accountable Act (the HFCAA) if the Public Company Accounting Oversight Board (the PCAOB) is unable to inspect our auditors for two consecutive years beginning in 2021.
• The company is required to complete the record filing requirement with the CSRC to list on overseas stock exchanges and may not be able to complete the filing because the filing materials are incomplete or do not meet the requirements of the CSRC.
• The company's founder, Chairperson of the Board of Directors and Chief Executive Officer, Ms. Xiaoqiu Zhang, has a significant influence over our company and future corporate decisions and her interests may not always be aligned with those of other shareholders.

Future Outlook

The company intends to retain most, if not all, of its available funds and any future earnings after this offering to the development and growth of the business in China and does not expect to pay dividends in the foreseeable future.

Industry Context

The beauty industry is highly competitive, with intense competition from both domestic and international players. The company faces challenges in establishing brand awareness and differentiating itself from competitors.

Comparison to Industry Standards

• The company competes with established multinational and domestic brands such as Fanwenhua, DR PLANT, and Beauty Farm, each with over 100 franchisees nationwide.
• These competitors have longer operating histories, higher market share, and established brand recognition, posing a challenge for Park Ha in gaining visibility and credibility.

Related Party Transactions

• The Company made advances to Mr. Hengquan Zhang for working capital to be paid on behalf of the Company.
• The Company made advances to Mr. Fujun Yu for working capital to be paid on behalf of the Company.
• The Company received advances from Mr. Fujun Yu as working capital.
• The Company received advances from Ms. Guozhen Liu as working capital.
• The Company received advances from Ms. Xiaoqiu Zhang as working capital.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Shareholders may face difficulties in protecting their interests due to the company's incorporation in the Cayman Islands.
• Shareholders may not receive dividends in the foreseeable future as the company intends to retain earnings for growth.
• Franchisees may benefit from the company's growth strategies and increased brand awareness.
• Employees may benefit from the company's expansion and potential job creation.

Next Steps

• The company needs to secure Nasdaq approval for its listing application.
• The company needs to complete the filing with the CSRC.
• The company intends to use the proceeds from this offering for expanding the scale of its directly-owned stores, purchasing existing product patents, and acquiring our ingredients suppliers.

Key Dates

Keywords

IPO, Park Ha Biological Technology, Nasdaq, skincare, cosmetics, franchise, China, ordinary shares, offering